A Food Effect Study of VC005 Tablets in Healthy Adult Subjects.

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07533851

Enrollment

Registered

2026-04-16

Start date

2026-04-23

Completion date

2026-05-29

Last updated

2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atopic Dermatitis

Brief summary

This study will adopt a randomized, open-label, two-period, 2-way crossover design to evaluate Food effect of VC005 Tablets in healthy subjects

Interventions

DRUGVC005 Tablets

Oral administration after fasting/high-fat meal

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 45 Years

Healthy volunteers

Yes

Inclusion criteria

1. Able and willing to give written informed consent before study, and fully understand the study content, process and possible adverse reactions; 2. Able to complete the study in compliance with the protocol; 3. Subject (including partner) is willing to voluntarily take effective contraceptive measures from screening through 3 months after the last dose of study drug ； 4. Male and female subjects between the ages of 18 and 45 years, inclusive; 5. At least 50.0kg for male subjects, 45.0kg for female subjects, with a Body Mass Index (BMI= Weight/Height2) between 19.0-26.0 kg/m2, inclusive;

Exclusion criteria

1. More than 5 cigarettes per day on average within 3 months prior to screening; 2. History of sensitivity to drugs similar to the study drug;allergic constitution (e.g. allergy to two or more kinds of drugs and food ); 3. History of drug and/or alcohol abuse (alcoholism defined as: drinking 14 units of alcohol per week: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine); history of drug abuse or or have used drugs within the past five years; 4. Donation or loss of a significant volume of blood (\> 400 mL) within 3 months prior to screening; 5. History of difficulties in swallowing or any history of gastrointestinal, liver, kidney disease (whether cured or not) or surgery that affects drug absorption or excretion； 6. Intake of any prescription drugs, over-the-counter drugs, vitamin or herbal medicine within 14 days prior to receiving study drug;

Design outcomes

Primary

Measure	Time frame
Maximum Observed Plasma Concentration (Cmax)	Day1-Day7
Area under the plasma concentration-time curve(AUC）	Day1-Day7

Countries

China

Contacts

PRINCIPAL_INVESTIGATORbicheng Liu

Zhongda Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 9, 2026